::: Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
Shares of Cempra, Initial Public Offering of Common Stock, Leerink Swann LLC, clinical-stage pharmaceutical company, treatment of bacterial infectious diseases, initial public offering of 8,400,000 shares, securities laws, Common Stock, Tony Russo, Russo Partners

::: Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
IDX184 phase IIb clinical trial, IDX184 Partial Clinical, phase IIb study evaluating IDX184, IDX184 Phase IIb StudyIn, ongoing phase IIb clinical trial, parallel group phase IIb clinical trial, interim phase IIb data, mg of IDX184, removal of the partial clinical, healthy volunteers of the combination of IDX184

::: CellaVision launches digital cell morphology system into the North American Veterinary market
CellaVision addresses, CellaVision AB, CellaVision DM96 Vet, large veterinary laboratories, larger veterinary laboratories, CEO of CellaVision, North American Veterinary market, veterinary tests, veterinary universities

::: Biofrontera AG - 500,000 shares subscribed in capital increase
supervisory board of Biofrontera AG, capital increase amount, base capital, issuing 500,000 new ordinary shares, registration of the shares, Werner Pehlemann, Hemmelrather Weg, private placement of the shares, supervisory board

::: Prima BioMed achieves major milestone - First patient enrolled in CANVAS Ovarian Cancer Vaccine Trial
CANVAS Ovarian Cancer Vaccine Trial, CVacTM ovarian cancer therapy vaccine, CVacTM ovarian cancer therapy treatment, CANcer VAccine Study, CVac ovarian cancer therapy vaccine, ovarian cancer patients, major CVacTM trial, Australian healthcare company Prima BioMed, patient trial, CVacTM vaccine